US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Quasi-New Stocks

685.75

-15.2311-2.17%

Number of Gainers:61

Number of Losers:84

Number of Flat:9

PE:- -

High:703.53

Open:700.98

Low:685.46

Close:700.98

Volume:313.13M

Turnover:10.17B

Market Cap:479.55B

Float Cap:364.16B

Loading ...

Eledon Pharmaceuticals Q2 Net Loss Widens on Warrant Liability Changes

Tenon Medical Q2 Revenue Jumps on Higher Surgical Procedure Volume

Uruguay's DLocal Q2 Revenue Jumps 56%, Beating Estimates on TPV Growth

Veritone Q2 Revenue Misses Estimates

Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process

DLocal Q2 Earnings, Revenue Rise

MT Newswires Live

Caribou Biosciences Q2 FY26 GAAP Net Loss Narrows to USD 24.3 Million; Revenue Falls to USD 1.5 Million

Inhibrx Biosciences Q2 Net Loss Widens on Higher Expenses

ProMIS Neurosciences Q2 Net Loss Widens

Rani Therapeutics Q2 FY26 Net Loss Narrows to USD 8.42 Million; Revenue Turns to USD 1.71 Million

DLocal Q2 EPS $0.18 Misses $0.19 Estimate, Sales $399.664M Beat $368.858M Estimate

Benzinga Earnings

Invivyd Q2 EPS USD -0.14

Dlocal Q2 Tpv $17.70 Bln

THOMSON REUTERS

Dlocal - Updates FY Guidance: Tpv Growth 60–70%, Gross Profit 25–30%, Operating Profit 27.5–32.5% Year-over-Year

THOMSON REUTERS

Dlocal Q2 Gross Margin 32%

THOMSON REUTERS

Dlocal Q2 EPS $0.18

THOMSON REUTERS

Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update

THOMSON REUTERS

Rani Therapeutics Q2 Operating Expenses USD 10.536 Million

THOMSON REUTERS

Press Release: dLocal Reports Second Quarter 2026 Financial Results

Press Release: Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/BK4539/news?page=33"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4539","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4539\",,,,,undefined,":{"symbol":"BK4539","market":"US","secType":"PLATE","nameCN":"Quasi-New Stocks","latestPrice":685.7458,"timestamp":1787601599999,"preClose":700.9769,"halted":0,"volume":313126904,"delay":0,"changeRate":-0.021728,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-15.23114,"latestTime":"08-24 16:00:00 EDT","open":700.9787,"high":703.53143,"low":685.4632,"amount":10165204650.256977,"amplitude":0.025776,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787644800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.245326,"peRate":150.969108,"turnoverRate":0.024191,"increases":61,"decrements":84,"flats":6,"marketCap":479546114433.625,"floatMarketCap":364158638649},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4539\",,,,,undefined,":{"symbol":"BK4539","high":703.53143,"amplitude":0.025776,"preClose":700.9769,"low":685.4632,"pbRate":"5.245326","latestPrice":685.7458,"volume":313126904,"delay":0,"open":700.9787,"prevYearClose":881.5255,"prevWeekClose":700.9769,"prevMonthClose":673.0273,"prevQuarterClose":742.922,"fiveDayClose":666.772,"twentyDayClose":702.6321,"sixtyDayClose":754.549,"secType":"PLATE","market":"US","turnoverRate":0.024191,"peRate":150.969108,"marketCap":479546114433.625,"floatMarketCap":364158638649,"timestamp":1787601599999,"nameCN":"Quasi-New Stocks"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4539\",,,,undefined,":{"bkCode":"BK4539","up":61,"down":84,"flat":9},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4539\",pageSize:20,pageCount:33,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659162006","title":"Eledon Pharmaceuticals Q2 Net Loss Widens on Warrant Liability Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162006","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162006?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:16","pubTimestamp":1786652214,"startTime":"0","endTime":"0","summary":"Eledon Pharmaceuticals Q2 net loss widens on warrant liability changesOverviewUS biotech reported Q2 net loss widened yr/yr, driven by non-cash warrant liability changesOperating expenses for Q2 fell ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A158:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PROK","UNCY","ELDN","BK4539","ACHV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659028162","title":"Tenon Medical Q2 Revenue Jumps on Higher Surgical Procedure Volume","url":"https://stock-news.laohu8.com/highlight/detail?id=2659028162","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659028162?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:15","pubTimestamp":1786652143,"startTime":"0","endTime":"0","summary":"Tenon Medical Q2 revenue jumps on higher surgical procedure volumeOverviewUS medical device maker's Q2 revenue rose 127% yr/yr on higher surgical procedure volumeQ2 gross profit up 232% yr/yr, gross m","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A14N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TELA","XTNT","BK4198","BK4139","BK4539","RNXT","TNON","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162027","title":"Uruguay's DLocal Q2 Revenue Jumps 56%, Beating Estimates on TPV Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162027","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162027?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:15","pubTimestamp":1786652124,"startTime":"0","endTime":"0","summary":"Uruguay's DLocal Q2 revenue jumps 56%, beating estimates on TPV growthOverviewUruguay cross-border payments platform's Q2 revenue rose 56%, beating analyst expectationsNet income for Q2 rose 28% year-","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A153:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","GLBE","BK4588","BK4227","DLO","BK4563","BK4106","BK4585","BK4220","BK4122"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162008","title":"Veritone Q2 Revenue Misses Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162008","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162008?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:15","pubTimestamp":1786652120,"startTime":"0","endTime":"0","summary":"Veritone Q2 revenue misses estimatesOverviewEnterprise AI solutions provider's Q2 revenue rose 5% yr/yr, missing analyst expectationsCompany completed first phase of restructuring, delivering $11.3 ml","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A14M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMWB","BK4579","CBRS","DH","BK4023","BK4141","LU2089985449.USD","BK4539","BK4543","BK4167","LU0274383776.USD","VERI","LU2931357623.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659952921","title":"Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process","url":"https://stock-news.laohu8.com/highlight/detail?id=2659952921","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659952921?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:15","pubTimestamp":1786652100,"startTime":"0","endTime":"0","summary":"Late-breaking Phase 2 CAD-1005 data presented at ISTH support a late-stage portfolio organized around preoperative safety, orphan regulatory acceleration, and postoperative shieldingPONTE VEDRA, Fla.,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/13/3344960/0/en/cadrenal-therapeutics-reports-second-quarter-2026-financial-results-provides-a-corporate-update-on-the-cardiac-acute-critical-care-franchise-and-the-strategic-partnering-process.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B66KJ199.SGD","BK4539","BK4134","BK4007","IE00B19Z4B17.USD","BK4166","KD","IE00B7SZL793.SGD","LENZ","CACC","BK4139","IE0031619046.USD","HIT","BK4173"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659620411","title":"DLocal Q2 Earnings, Revenue Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2659620411","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659620411?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:14","pubTimestamp":1786652054,"startTime":"0","endTime":"0","summary":"DLocal (DLO) reported Q2 earnings late Thursday of $0.18 per diluted share, up from $0.14 a year earlier.Analysts polled by FactSet expected $0.18.Revenue for the three months ended June 30 was $399.7 million, up from $256.5 million a year earlier.Analysts expected $366.8 million.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4227","BK4106","BK4539","BK4563","BK4588","DLO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659273162","title":"Caribou Biosciences Q2 FY26 GAAP Net Loss Narrows to USD 24.3 Million; Revenue Falls to USD 1.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659273162","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659273162?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:13","pubTimestamp":1786652037,"startTime":"0","endTime":"0","summary":"Caribou Biosciences Q2 FY26 GAAP net loss narrows to USD 24.3 million; revenue falls to USD 1.5 millionCaribou Biosciences posted a GAAP net loss of USD 24.3 million, or USD 0.24 per share, in Q2 2026.Loss narrowed from USD 54.1 million, or USD 0.58 per share, a year earlier, which included USD 21.3 million in non-cash impairment.Revenue fell 43.8% to USD 1.5 million versus Q2 2025.R&D expenses dropped 31.6% to USD 18.9 million, due to lower external CMO/CRO activity and prior workforce reduction.Cash, cash equivalents and marketable securities totaled USD 113.8 million; runway expected to extend to end-2027, with funding options explored for ANTLER-3.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caribou Biosciences Inc. published the","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDLc0p1ND:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","CRBU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162218","title":"Inhibrx Biosciences Q2 Net Loss Widens on Higher Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162218","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162218?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:12","pubTimestamp":1786651973,"startTime":"0","endTime":"0","summary":"Inhibrx Biosciences Q2 net loss widens on higher expensesOverviewUS biopharmaceutical firm's Q2 2026 revenue was zero, down from prior-year periodNet loss for Q2 widened yr/yr as operating expenses in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A14A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","ERAS","CLRB","BK4563","BK4139","INBX","IMNM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162415","title":"ProMIS Neurosciences Q2 Net Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162415","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162415?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:10","pubTimestamp":1786651823,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences Q2 net loss widensOverviewUS biotechnology firm's Q2 net loss widened yr/yrCash and short-term investments rose to $53.4 mln, funding operations through 2027Company reported posit","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A13R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANNX","BK4139","PMN","ABOS","BK4539","MGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162468","title":"Rani Therapeutics Q2 FY26 Net Loss Narrows to USD 8.42 Million; Revenue Turns to USD 1.71 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162468","media":"Reuters","labels":["shareholding","corporation","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162468?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:10","pubTimestamp":1786651818,"startTime":"0","endTime":"0","summary":"Rani Therapeutics Q2 FY26 net loss narrows to USD 8.42 million; revenue turns to USD 1.71 millionRani Therapeutics posted a Q2 net loss of USD 8.4 million, narrowing from USD 11.2 million a year earli","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDLBssyl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,corporation,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","RANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162939","title":"DLocal Q2 EPS $0.18 Misses $0.19 Estimate, Sales $399.664M Beat $368.858M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162939","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162939?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:06","pubTimestamp":1786651584,"startTime":"0","endTime":"0","summary":"DLocal (NASDAQ:DLO) reported quarterly earnings of $0.18 per share which missed the analyst consensus estimate of $0.19 by 5.26 percent. This is a 28.57 percent increase over earnings of $0.14 per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61192214/dlocal-q2-eps-0-18-misses-0-19-estimate-sales-399-664m-beat-368-858m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"DLocal Q2 EPS $0.18 Misses $0.19 Estimate, Sales $399.664M Beat $368.858M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4588","BK4227","DLO","BK4563","BK4106","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659626931","title":"Invivyd Q2 EPS USD -0.14","url":"https://stock-news.laohu8.com/highlight/detail?id=2659626931","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659626931?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:06","pubTimestamp":1786651563,"startTime":"0","endTime":"0","summary":"BRIEF-Invivyd Q2 EPS USD -0.14Aug 13 (Reuters) - Invivyd Q2 net income USD -44.393 million.Q2 revenue USD 14.285 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nPLXFW5MJJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IVVD","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659682162","title":"Dlocal Q2 Tpv $17.70 Bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2659682162","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659682162?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651503,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nPLXKZ367X:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DLO","BK4539","BK4588","BK4585","BK4106","BK4227","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659621521","title":"Dlocal - Updates FY Guidance: Tpv Growth 60–70%, Gross Profit 25–30%, Operating Profit 27.5–32.5% Year-over-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2659621521","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659621521?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651503,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nPLXKZ367X:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4539","DLO","BK4106","BK4563","BK4588","BK4227"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659368162","title":"Dlocal Q2 Gross Margin 32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659368162","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659368162?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651503,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nPLXKZ367X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4563","BK4106","BK4585","DLO","BK4227","BK4588","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162653","title":"Dlocal Q2 EPS $0.18","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162653","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162653?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651503,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nPLXKZ367X:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DLO","BK4539","BK4588","BK4585","BK4106","BK4227","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659522162","title":"Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659522162","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659522162?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651502,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nTUA4MLGG0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","RANI","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162345","title":"Rani Therapeutics Q2 Operating Expenses USD 10.536 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162345","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162345?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651502,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nPLXRNXP6L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RANI","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659616261","title":"Press Release: dLocal Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2659616261","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659616261?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"quarter of 2026, up 92% year-over-year compared to US$9.2 billion in the. second quarter of 2025 and up 26% compared to US$14.1 billion in the. first quarter of 2026. In constant currency, TPV growth for the period. -- Revenues amounted to US$399.7 million, up 56% year-over-year compared to. US$256.5 million in the second quarter of 2025 and up 19% compared to. US$335.9 million in the first quarter of 2026. In constant currency,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4106","BK4563","BK4227","DLO","BK4539","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162993","title":"Press Release: Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162993","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162993?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"-- Achieved Q2 2026 PEMGARDA  net product revenue of $14.3. million, representing 21% growth versus Q2 2025 net product revenue of. -- Completed rapid enrollment in VYD2311 DECLARATION clinical trial. expansion cohort and LIBERTY clinical trial, driven by strong subject. -- DECLARATION pivotal clinical trial enrollment is complete; the ongoing. study is approaching its planned analysis, and in lieu of a Q2 2026. quarterly earnings call, Invivyd plans to hold an investor call post. -- Strong balance sheet with Q2 2026 ending cash and cash equivalents of. $160.1 million anticipated to provide runway through DECLARATION pivotal. data readout and support potential commercial launch readiness for. 30, 2026, compared to $11.8 million in for the quarter ended June 30,-- In July 2026, Invivyd announced receipt of twelve months' advanced notice. of emergency use authorization  termination for PEMGARDA and that. the company is in dialogue with the U.S. Food and Drug Administration.  about approp","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4551","BK4535","BK4585","BK4539","IVVD","MEDX","NVIB","BK4568","GDOC","R","BNTX","IDNA","BK4022","HYLG","BK4548","IND","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":54,"pageCount":33,"totalSize":1080,"code":"91000000","status":"200"}]}}